Robert Olstein
Olstein Capital Management
Robert Olstein Thermo Fisher Scientific Inc stake
total: 342
Olstein Capital Management TMO trades
- Total transactions:
- 12
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 7
- Held since:
- 2025 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Robert Olstein doesn't hold any Thermo Fisher Scientific Inc (TMO) shares. To date, the estimated cost basis is nearly $409.11 for "buy" trades and estimated average "sell" price is $508.38. Olstein Capital Management first purchased TMO in 2017 Q2, initially acquiring 23,000 shares. Robert Olstein later completely sold out the position and invested in Thermo Fisher Scientific Inc again in 2025 Q2. Since the initial investment in Thermo Fisher Scientific Inc (TMO), Olstein Capital Management has made 11 more transactions.
When did Robert Olstein sell Thermo Fisher Scientific Inc (TMO)?
Robert Olstein sold off the entire Thermo Fisher Scientific Inc (TMO) position in 2026 Q2.
When did Robert Olstein buy Thermo Fisher Scientific Inc (TMO)?
Robert Olstein first invested in Thermo Fisher Scientific Inc (TMO) in 2017 Q2 at the reported quarter-end price of $174.48 per share.
What's the cost basis of Olstein Capital Management's TMO stake?
The estimated cost basis for Thermo Fisher Scientific Inc (TMO) stake is around $409.11 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $409.11
- Weighted AVG sell price:
- $508.38
Robert Olstein's historical trades in Thermo Fisher Scientific Inc
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$491.56
|
|
-100% (-6,750)
|
-0.72%
|
|
2026 Q1
|
0.72%
|
6,750
|
$491.56
|
$3,318,000
|
+5.47% (+350)
|
+0.04%
|
|
2025 Q4
|
0.76%
|
6,400
|
$579.38
|
$3,708,000
|
-20.00% (-1,600)
|
-0.18%
|
|
2025 Q2
|
0.61%
|
8,000
|
$405.50
|
$3,244,000
|
new
|
+0.61%
|
|
2020 Q3
|
0.00%
|
$362.29
|
-100% (-7,000)
|
|||
|
2020 Q2
|
0.47%
|
$362.29
|
-26.32% (-2,500)
|
|||
|
2019 Q4
|
0.48%
|
$324.84
|
-9.52% (-1,000)
|
|||
|
2019 Q2
|
0.50%
|
$293.71
|
-12.50% (-1,500)
|
|||
|
2019 Q1
|
0.54%
|
$273.75
|
-4.00% (-500)
|
|||
|
2018 Q4
|
0.46%
|
$223.76
|
-43.18% (-9,500)
|
|||
|
2018 Q3
|
0.72%
|
$244.09
|
-4.35% (-1,000)
|
|||
|
2017 Q2
|
0.51%
|
$174.48
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.